UX007
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glucose Transporter Type 1 Deficiency Syndrome
Conditions
Glucose Transporter Type 1 Deficiency Syndrome
Trial Timeline
Sep 10, 2015 → Oct 22, 2019
NCT ID
NCT02599961About UX007
UX007 is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Glucose Transporter Type 1 Deficiency Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02599961. Target conditions include Glucose Transporter Type 1 Deficiency Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02599961 | Phase 2 | Terminated |
| NCT02214160 | Phase 2 | Completed |
| NCT01886378 | Phase 2 | Completed |
Competing Products
17 competing products in Glucose Transporter Type 1 Deficiency Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin + Alpha lipoic acid + Olmesartan + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Exenatide + Metformin | Eli Lilly | Approved | 85 |
| AZD1656 | AstraZeneca | Phase 1 | 33 |
| Candesartan + Placebo | AstraZeneca | Approved | 85 |
| Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg | Merck | Phase 2 | 52 |
| Sitagliptin-Metformin + Metformin + Placebo pill | Merck | Approved | 85 |
| Comparator: exenatide + Comparator: exenatide + Comparator: Placebo | Merck | Phase 1 | 33 |
| Placebo + Januvia | Merck | Phase 2 | 52 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| Ramipril + Rosiglitazone | Pfizer | Phase 3 | 76 |
| HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| GFT505 80mg + Placebo | Genfit | Phase 2 | 44 |